Modalis Therapeutics Corp is a Japan-based company engaged in the research and development of gene therapy drugs using the core platform CRISPR-GNDM technology. The Company develops gene therapy drugs that use CRISPR-GNDM technology, which is a unique platform technology, for genetic diseases caused by errors in the genetic code and epigenetics. The Company has two business models. Collaborative model pipeline opens CRISPR-GNDM technology to partners, and develops therapeutic drugs with partners' funds for the targets selected by the partners. In-house model pipeline selects targets using the Company's own CRISPR-GNDM technology and develops therapeutic agents. The Company's pipeline consists of a collaborative model pipeline of 5 items such as MDL-201 and an in-house model pipeline of 2 items such as MDL-101.

Employees

Sector

Biotechnology & Medical Research

Calendar

Earnings release - Q2 2026

More about the company

Quotes

Date	Price	Change	Volume
26-06-30	JP¥32.00	-3.03%	103,000
26-06-30	JP¥33.00	+3.12%	737,300
26-06-29	JP¥32.00	+6.67%	1,163,400
26-06-26	JP¥30.00	-3.23%	346,300
26-06-25	JP¥31.00	-6.06%	2,056,700

Delayed Quote Japan Exchange

More quotes

Income Statement and Estimates

More financial data

Annual profits - Rate of surprise

Company calendar

Delayed Japan Exchange Other stock markets 20:38:16 2026-06-30 EDT			5-day change	1st Jan Change
32.00 ^JPY	-3.03%		-3.03%	-42.86%

06-11	Modalis Therapeutics Corporation announced that it has received ¥2.64 million in funding from Evolution Capital Management LLC	CI
05-26	Modalis Therapeutics Corporation announced that it expects to receive ¥2.64 million in funding from Evolution Capital Management LLC	CI

Market Cap	3.18B 19.56M 17.12M 15.8M 14.74M 27.77M 1.85B 28.27M 190M 73.59M 913M 73.48M 71.84M	P/E 2024	-3.57x	P/E 2025	-2.01x
Enterprise Value	367M 2.26M 1.98M 1.82M 1.7M 3.21M 213M 3.26M 21.88M 8.5M 105M 8.48M 8.29M	EV / Sales 2024	-	EV / Sales 2025	-
Free-Float	90.35%	Yield 2024 *	-	Yield 2025	-

06-11	Modalis Therapeutics Corporation announced that it has received ¥2.64 million in funding from Evolution Capital Management LLC	CI
05-26	Modalis Therapeutics Corporation announced that it expects to receive ¥2.64 million in funding from Evolution Capital Management LLC	CI
02-12	Modalis Therapeutics Corporation Reports Earnings Results for the Full Year Ended December 31, 2025	CI
25-08-25	Modalis Therapeutics Corporation announced that it has received ¥3.072 million in funding from Evolution Capital Management LLC	CI
25-08-06	Modalis Therapeutics Corporation announced that it expects to receive ¥3.072 million in funding from Evolution Capital Management LLC	CI
25-07-06	Modalis Therapeutics Licenses Gene Therapy IP from Broad Institute for Muscular Dystrophy Treatment	MT
25-06-15	Modalis Issues Restricted Stock to Subsidiary Employee Under Incentive Plan	MT
25-06-09	SOLVE FSHD and Modalis Announce Strategic Collaboration to Develop an Innovative CRISPR-Based Epigenome Editing Treatment for Facioscapulohumeral Muscular Dystrophy	CI
25-04-30	Modalis Issues 21,900 Shares for Restricted Stock Remuneration	MT
25-01-27	Modalis Therapeutics Secures Japanese Patent for Gene Therapy	MT
25-01-06	JCR Pharmaceuticals and Modalis Therapeutics Advance Gene Therapy Research for CNS Disease	MT
25-01-05	Jcr Pharmaceuticals Co., Ltd. and Modalis Therapeutics Corporation Announces Transition to the Next Phase of Joint Research Agreement for Development of Novel Gene Therapy	CI
24-09-30	Modalis Therapeutics Corporation Receives FDA Grants Rare Pediatric Disease Designation to MDL-101 for the Treatment of Congenital Muscular Dystrophy Type 1a (LAMA2-CMD)	CI

12-24	Modalis Announces Publication in Human Gene Therapy of Study Demonstrating Efficient LAMA1 Gene Activation for the Treatment of LAMA2-CMD	BU
25-05-12	Modalis has been selected as a finalist in the XPRIZE Healthspan FSHD Bonus Prize Competition and awarded research funds.	BU
25-01-05	JCR Pharmaceuticals and Modalis Therapeutics Announce Transition to the Next Phase of Joint Research Agreement for Development of Novel Gene Therapy	BU
24-10-28	Modalis Therapeutics - MDL-101 for the Treatment of Congenital Muscular Dystrophy Type 1a has been granted Orphan Drug Designation in the US by the Food and Drug Administration	AQ
24-10-25	Modalis Therapeutics has received an Orphan Drug Designation from the U.S. Food and Drug Administration for MDL-101, a treatment for congenital muscular dystrophy type 1A (LAMA2-CMD).	BU

Modalis Therapeutics Corporation Stock

Stocks

4883

JP3922600006

Biotechnology & Medical Research

Valuation: Modalis Therapeutics Corporation

Chart: Modalis Therapeutics Corporation

Latest news : Modalis Therapeutics Corporation

Press Releases: Modalis Therapeutics Corporation

Quotes and Performance

Course Extremes

Managers and Directors: Modalis Therapeutics Corporation

Latest insider transactions

Bio Therapeutic Drugs

Financials

Company Profile

Quotes

Income Statement and Estimates

Annual profits - Rate of surprise

1 day	-3.03%
1 week	-3.03%
Current month	-3.03%
1 month	-25.58%
3 months	-45.76%
6 months	-44.83%
Current year	-42.86%

Manager	Title	Age	Since
Haru Morita CEO	Chief Executive Officer	56	2015-12-31
Naoki Kobayashi DFI	Director of Finance/CFO	62	-
Tetsuya Yamagata CTO	Chief Tech/Sci/R&D Officer	-	-

Director	Title	Age	Since
Joseph McCracken BRD	Director/Board Member	72	2018-07-31
Toshio Furuta BRD	Director/Board Member	64	2018-11-30
Haru Morita BRD	Director/Board Member	56	2015-12-31

Date	Insider	Type	Main position	Quantity	% Market Cap.
24-09-23	Osamu Nureki	Others	Founder	6,000	0.0132%
24-09-23	Osamu Nureki	Others	Founder	64,400	0.1419%
24-09-23	Osamu Nureki	Others	Founder	375,600	0.8278%

Add to a list 0 selected To use this feature you must be a member Log in Sign up	Change	5-day change	1-year change	3-year change	Capi.($)
MODALIS THERAPEUTICS CORPORATION	-3.03%	-3.03%	-60.00%	-88.49%	19.04M
ARGENX SE	+3.31%	-0.20%	+72.71%	+128.31%	55.78B
WUXI APPTEC CO., LTD.	-1.32%	+17.12%	+79.02%	+99.82%	55.66B
BIONTECH SE	-1.28%	+2.68%	-12.60%	-13.79%	23.84B
INSMED INCORPORATED	+1.79%	+4.38%	+5.94%	+405.31%	22.7B
GENMAB A/S	+4.45%	+5.06%	+36.50%	-30.43%	16.12B
EXELIXIS, INC.	+0.24%	+5.98%	+23.45%	+184.72%	13.64B
PHARMAESSENTIA CORPORATION	+5.51%	+22.37%	+171.36%	+338.01%	14.8B
MADRIGAL PHARMACEUTICALS, INC.	+1.83%	+4.58%	+77.42%	+132.45%	12.16B
CYTOKINETICS, INCORPORATED	-2.37%	+6.47%	+157.84%	+161.16%	11.85B
Average	+0.91%	+4.81%	+55.16%	+131.71%	22.66B
Weighted average by Cap.	+1.20%	+4.84%	+64.19%	+141.83%

	2024	2025
Net sales	-	-
Net income	-1.32B -8.1M -7.09M -6.55M -6.11M -11.51M -766M -11.71M -78.53M -30.49M -378M -30.44M -29.76M	-2.15B -13.24M -11.59M -10.7M -9.98M -18.8M -1.25B -19.14M -128M -49.82M -618M -49.74M -48.63M
Net Debt	-3.58B -21.99M -19.25M -17.77M -16.58M -31.23M -2.08B -31.79M -213M -82.76M -1.03B -82.63M -80.79M	-2.81B -17.3M -15.14M -13.98M -13.04M -24.57M -1.64B -25.01M -168M -65.09M -807M -65M -63.54M

1 week	30	34
1 month	30	45
Current year	30	83
1 year	30	103
3 years	30	287
5 years	30	1,741
10 years	30	4,070